Drug combination for stage IV melanoma shows success in trial

A new study examined the combination of the common immunotherapy drug pembrolizumab (Keytruda) with all-trans retinoic acid (ATRA), a chemotherapy drug that targets myeloid-derived suppressor cells. Researchers found that the drug combination is effective, with an overall response rate of 71%. Fifty percent of patients experienced a complete response, and the one-year overall survival rate was 80%.

from Latest Science News -- ScienceDaily https://ift.tt/gMcrAVp

Comments

Popular posts from this blog

Seismic study reveals key reason why Patagonia is rising as glaciers melt

New method to detect and visualize sperm cells recovered from forensic evidence